Canopy Growth Corporation: 3 Key Takeaways for Long-Term Investors

On its second-quarter fiscal 2027 earnings call, held on Nov. 6, 2026, Canopy Growth Corporation (CGC -3.58%) announced consolidated net revenue increased 22% year over year to $81.4 million. This top-line expansion demonstrates that expanding international distribution and improving cultivation efficiency can reaccelerate revenue growth across core markets. Three takeaways from the call stand out for long-term investors.

1. European Certification Unlocks International Growth Channels

European Union Good Manufacturing Practice (EU GMP) certification sets the regulatory quality standard required to sell medical cannabis in Europe. Canopy Growth earned this certification across its entire supply chain, so it doesn’t need third parties handling its products as it expands into European markets.

This makes Canopy the only Canadian company with end to end EU GMP certification covering its entire supply chain, from cultivation to the manufacturing and primary packaging of sublingual oils and dry cannabis flower.
— Luc Mongeau, Chief Executive Officer

2. Cultivation Upgrades Target Higher Yields and Lower Unit Costs

Canopy Growth is applying master grower techniques from its acquired business, MTL Cannabis, to upgrade its main facility in Kincardine. Higher yield per square foot reduces per-unit costs, so the company doesn’t need extra real estate to expand output.

We believe there is the potential to increase flower production at Kincardine by at least 25% to 30% within the same physical footprint. We expect increased yield and quality to drive both revenue growth and per unit cost improvements.
— Luc Mongeau, Chief Executive Officer

3. Cost Discipline Drives a Path Toward Positive Adjusted EBITDA

Canopy Growth reduced selling, general, and administrative (SG&A) expenses, or operational overhead, while integrating acquired businesses. Reduced overhead and higher-margin international sales support management’s target to reach positive adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA), a key measure of core operating profitability.

This strong execution reinforces our confidence as we remain on track to deliver positive adjusted EBITDA in the second half of this fiscal year.
— Thomas Carlton Stewart, Chief Financial Officer

Looking Ahead

International demand and refined cultivation techniques are pushing top-line momentum, and the business shows clear operational progress. Fully certified Canadian supply chain infrastructure and proprietary brand genetics position the business to capture European medical share while maintaining strict operational discipline.

We continue to strengthen our foundation, our capabilities, which gives me increasing confidence in our ability to accelerate growth into profitability in the coming quarters.
— Luc Mongeau, Chief Executive Officer

Upgrading cultivation facilities and streamlining European distribution channels remain key priorities to secure long-term leadership.

Elevating cultivation is a priority in the business. It is what will drive the biggest transformation of our P&L and our profitability.
— Luc Mongeau, Chief Executive Officer

The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Source: www.fool.com — article syndicated from the publisher’s feed; all rights remain with the original publisher.